Typically, $100,000 to $150,000 per quality-adjusted life-year is accepted as cost-effective, but Avastin as a first-line treatment was associated with a $240,814 price tag per QALY. As a second-line treatment, Avastin cost $363,066 per QALY.
The drug may become cost-effective if a biomarker to identify the patients who would most benefit was discovered. Researchers have yet to identify such a biomarker.
More articles on gastroenterology:
Balloon colonoscope improves polyp detection
10 statistics on gastroenterologist salary by subspecialty
Gastroenterologists & ACOs: In or out?
